Antisense oligonucleotides to Syk kinase: A novel therapeutic approach for respiratory disorders

Current Opinion in Investigational Drugs

Volumn 4, Issue 5, 2003, Pages 552-555

  Ulanova, Marina ^a   Puttagunta, Lakshmi ^a   Kim, Moo Kyung ^b   Schreiber, Alan D ^b   Befus, A Dean ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisense oligonucleotide; Inflammatory respiratory diseases; Non receptor protein tyrosine kinase; Syk

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; LIPOSOME; LUNG SURFACTANT; PICEATANNOL; PROTEIN TYROSINE KINASE;

AEROSOL; AIRWAY; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TYPE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG TOXICITY; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; LOW DRUG DOSE; NEBULIZATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RESPIRATORY TRACT DISEASE; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENZYME PRECURSORS; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-TYROSINE KINASES; RESPIRATORY HYPERSENSITIVITY;

EID: 0037504176     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, Nagai K, Yamada T, Nakamura S, Yamamura H: Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem (1991) 266(24):15790-15796.
2. Hatada MH, Lu X, Laird ER, Green J, Morgenstern JP, Lou M, Marr CS, Phillips TB, Ram MK, Theriault K: Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature (1995) 377(6544):32-38.
3. Futterer K, Wong J, Grucza RA, Chan AC, Waksman G: Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol (1998) 281(3):523-537.
4. Darby C, Geahlen RL, Schreiber AD: Stimulation of macrophage Fcγ RIIIA activates the receptor-associated protein tyrosine kinase Syk and induces phosphorylation of multiple proteins including p95Vav and p62/GAP-associated protein. J Immunol (1994) 152(11):5429-5437. Report of the first study demonstrating critical involvement of Syk in Fcγ receptor-mediated signaling in macrophages.
5. Indik ZK, Park JG, Hunter S, Schreiber AD: The molecular dissection of Fcγ receptor mediated phagocytosis. Blood (1995) 86(12):4389-4399.
6. Indik ZK, Park JG, Pan XQ, Schreiber AD: Induction of phagocytosis by a protein tyrosine kinase. Blood (1995) 85(5):1175-1180.
7. Taylor JA, Karas JL, Ram MK, Green OM, Seidel-Dugan C: Activation of the high-affinity immunoglobulin E receptor FcεRI in RBL-2H3 cells is inhibited by Syk SH2 domains. Mol Cell Biol (1995) 15(8):4149-4157.
8. Zhang J, Berenstein EH, Evans RL, Siraganian RP: Transfection of Syk protein tyrosine kinase reconstitutes high affinity IgE receptor-mediated degranulation in a Syk-negative variant of rat basophilic leukemia RBL-2H3 cells. J Exp Med (1996) 184(1):71-79.
9. Costello PS, Turner M, Walters AE, Cunningham CN, Bauer PH, Downward J, Tybulewicz VL: Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. Oncogene (1996) 13(12):2595-2605. Using Syk-deficient mast cells, an essential role for Syk in FcεRI signaling was demonstrated.
10. Matsuda M, Park JG, Wang DC, Hunter S, Chien P, Schreiber AD: Abrogation of the Fcγ receptor IIA-mediated phagocytic signal by stemloop Syk antisense oligonucleotides. Mol Biol Cell (1996) 7(7):1095-1106. Describes the design of the first antisense to Syk. The efficacy of stem-loop Syk antisense for targeting and degrading Syk mRNA, particularly for inhibition of Fcγ receptor-mediated phagocytosis, was demonstrated.
11. Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T: The Syk protein tyrosine kinase is essential for Fcγ receptor signaling in macrophages and neutrophils. Mol Cell Biol (1998) 18(7):4209-4220.
12. Lin TH, Rosales C, Mondal K, Bolen JB, Haskill S, Juliano RL: Integrin-mediated tyrosine phosphorylation and cytokine message induction in monocytic cells. A possible signaling role for the Syk tyrosine kinase. J Biol Chem (1995) 70(27):16189-16197. Syk was identified as an important component of an integrin signaling pathway in monocytic cells, leading to activation of NFκB and to increased levels of cytokine messages.
13. Yan SR, Berton G: Antibody-induced engagement of β2 integrins in human neutrophils causes a rapid redistribution of cytoskeletal proteins, Src-family tyrosine kinases, and p72Syk that precedes de novo actin polymerization. J Leukocyte Biol (1998) 64(3):401-408.
14. Reyes-Reyes M, Mora N, Gonzalez G, Rosales C: β1 and β2 integrins activate different signalling pathways in monocytes. Biochem J (2002) 363(Pt 2):273-280.
15. Mocsai A, Zhou M, Meng F, Tybulewicz VL, Lowell CA: Syk is required for integrin signaling in neutrophils. Immunity (2002) 16(4):547-558.
16. Woodside DG, Obergfell A, Talapatra A, Calderwood DA, Shattil SJ, Ginsberg MH: The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin β cytoplasmic domains. J Biol Chem (2002) 277(42):39401-39408.
17. Sada K, Takano T, Yanagi S, Yamamura H: Structure and function of Syk protein-tyrosine kinase. J Biochem (2001) 130(2):177-186.
18. Greenberg S, Chang P, Silverstein SC: Tyrosine phosphorylation of the γ subunit of Fcγ receptors, p72Syk, and paxillin during Fc receptor-mediated phagocytosis in macrophages. J Biol Chem (1994) 269(5):3897-3902.
19. Benhamou M, Gutkind JS, Robbins KC, Siraganian RP: Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc Natl Acad Sci USA (1990) 87(14):5327-5330.
20. Hutchcroft JE, Geahlen RL, Deanin GG, Oliver JM: FcεRI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells. Proc Natl Acad Sci USA (1992) 89(19):9107-9111.
21. Benhamou M, Ryba NJ, Kihara H, Nishikata H, Siraganian RP: Protein-tyrosine kinase p72syk in high affinity IgE receptor signaling. Identification as a component of pp72 and association with the receptor γ chain after receptor aggregation. J Biol Chem (1993) 268(31):23318-23324.
22. Kepley CL, Youssef L, Andrews RP, Wilson BS, Oliver JM: Syk deficiency in nonreleaser basophils. J Allergy Clin Immunol (1999) 104(2 Pt 1):279-284.
23. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU: Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med (1996) 183(4):1407-1414.
24. Yan SR, Huang M, Berton G: Signaling by adhesion in human neutrophils: Activation of the p72Syk tyrosine kinase and formation of protein complexes containing p72Syk and Src family kinases in neutrophils spreading over fibrinogen. J Immunol (1997) 158(4):1902-1910.
25. Hunter S, Kamoun M, Schreiber AD: Transfection of an Fcγ receptor cDNA induces T cells to become phagocytic. Proc Natl Acad Sci USA (1994) 91(21):10232-10236.
26. Weiss A, Littman DR: Signal transduction by lymphocyte antigen receptors. Cell (1994) 76(2):263-274.
27. Chan AC, Desai DM, Weiss A: The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol (1994) 12:555-592.
28. Brumbaugh KM, Binstadt BA, Billadeau DD, Schoon RA, Dick CJ, Ten RM, Leibson PJ: Functional role for Syk tyrosine kinase in natural killer cell-mediated natural cytotoxicity. J Exp Med (1997) 186(12):1965-1974.
29. Watson SP, Gibbins J: Collagen receptor signalling in platelets: Extending the role of the ITAM. Immunol Today (1998) 19(6):260-264.
30. Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC: The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature (2000) 406(6797):742-747. The first demonstration of Syk in epithelial cells. The study suggests that Syk may be a negative regulator of breast tumor growth.
31. Yamada T, Fujieda S, Yanagi S, Yamamura H, Inatome R, Sunaga H, Saito H: Protein-tyrosine kinase Syk expressed in human nasal fibroblasts and its effect on RANTES production. J Immunol (2001) 166(1):538-543.
32. Tsuchida S, Yanagi S, Inatome R, Ding J, Hermann P, Tsujimura T, Matsui N, Yamamura H: Purification of a 72-kDa protein-tyrosine kinase from rat liver and its identification as Syk: Involvement of Syk in signaling events of hepatocytes. J Biochem (2000) 127(2):321-327.
33. Yanagi S, Inatome R, Ding J, Kitaguchi H, Tybulewicz VL, Yamamura H: Syk expression in endothelial cells and their morphologic defects in embryonic Syk-deficient mice. Blood (2001) 98(9):2869-2871.
34. Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL: Inhibition of mast cell Fcε R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem (1994) 269(47):29697-29703.
35. Wolter F, Clausnitzer A, Akoglu B, Stein J: Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr (2002) 132(2):298-302.
36. Miura K, Lavens-Phillips S, MacGlashan DW Jr: Piceatannol is an effective inhibitor of IgE-mediated secretion from human basophils but is neither selective for this receptor nor acts on syk kinase at concentrations where mediator release inhibition occurs. Clin Exp Allergy (2001) 31(11):1732-1739.
37. Dekker FJ, De Mol NJ, Van Ameijde J, Ficher MJ, Ruijtenbeek R, Redegeld FA, Liskamp RM: Replacement of the intervening amino acid sequence of a Syk-binding diphosphopeptide by a nonpeptide spacer with preservation of high affinity. Chembiochem (2002) 3(2-3):238-242.
38. Mahabeleshwar GH, Kundu GC: Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor κB-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3′-kinase activity in breast cancer cells. J Biol Chem (2003) 278(8):6209-6221.
39. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol (1992) 41(6):1023-1033.
40. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A: Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun (1993) 197(2):818-825.
41. Zelphati O, Szoka FC Jr: Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res (1996) 13(9):1367-1372.
42. Stenton GR, Kim MK, Nohara O, Chen CF, Hirji N, Wills FL, Gilchrist M, Hwang PH, Park JG, Finlay W, Jones RL et al: Aerosolized Syk antisense suppresses Syk expression, mediator release from macrophages, and pulmonary inflammation. J Immunol (2000) 164(7):3790-3797.
43. Nyce JW, Metzger WJ: DNA antisense therapy for asthma in an animal model. Nature (1997) 385(6618):721-725.
44. Allakhverdi Z, Allam M, Renzi PM: Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common β chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. Am J Respir Crit Care Med (2002) 165(7):1015-1021.
45. Finotto S, Buerke M, Lingnau K, Schmitt E, Galle PR, Neurath MF: Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol (2001) 107(2):279-286.
46. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, Bartsch B, Atreya R, Schmitt E, Galle PR, Renz H et al: Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med (2001) 193(11):1247-1260.
47. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, Puttagunta L, Musat-Marcu S, James D, Schreiber AD, Befus AD: Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol (2002) 169(2):1028-1036. Reports that antisense to Syk delivered in liposome complexes to the airways significantly suppresses many of the central components of allergic asthma and inflammation.
48. Crooke ST: Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta (1999) 1489(1):31-44. A comprehensive review on the mechanisms of action of antisense oligonucleotides.
49. Stein CA: Is irrelevant cleavage the price of antisense efficacy? Pharmacol Ther (2000) 85(3):231-236.
50. Guvakova MA, Yakubov LA, Vlodavsky I, Tonkinson JL, Stein CA: Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem (1995) 270(6):2620-2627.
51. Fennewald SM, Rando RF: Inhibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J Biol Chem (1995) 270(37):21718-21721.
52. Bjorck T, Gustafsson LE, Dahlen SE: Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis (1992) 145(5):1087-1091.
53. Ali S, Mustafa SJ, Metzger WJ: Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: Evidence for an inducible adenosine A1 receptor. J Pharmacol Exp Ther (1994) 268(3):1328-1334.
54. Maus U, Rosseau S, Mandrakas N, Schlingensiepen R, Maus R, Muth H, Grimminger F, Seeger W, Lohmeyer J: Cationic lipids employed for antisense oligodeoxynucleotide transport may inhibit vascular cell adhesion molecule-1 expression in human endothelial cells: A word of caution. Antisense Nucleic Acid Drug Dev (1999) 9(1):71-80. Implicates importance of further study of non-sequence-specific effects of antisense drugs, particularly those dependent on liposome carriers.
55. Lebedeva I, Stein CA: Antisense oligonucleotides: Promise and reality. Annu Rev Pharmacol Toxicol (2001) 41:403-419.